Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.62 |
| ▸ | TERT | O14746 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 4/20 | 0.52 |
| ▸ | TK1 | P04183 | 2/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | POLD1 | P28340 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29671382 | 0.95 | F2 (0.68) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL29775052 | 0.95 | F2 (0.68) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL29350192 | 0.95 | F2 (0.68) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL29415903 | 0.95 | F2 (0.68) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL34463741 | 0.95 | F2 (0.68) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL17742358 | 0.92 | F2 (0.57) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL15672415 | 0.92 | F2 (0.65) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL18362678 | 0.92 | F2 (0.59) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL18760797 | 0.92 | F2 (0.59) | F2TERTPOLBP2RY2P2RY4 | |
| SCHEMBL18760794 | 0.92 | F2 (0.59) | F2TERTPOLBP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| CN-117545509-A | Oral delivery of oligonucleotides | 四纬生物制药股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| WO-2024030909-A1 | BIOMARKERS OF AMINO ACID COMPOSITION TREATMENT RESPONSE IN LONG COVID | AXCELLA HEALTH INC. (US) | 2024-02-08 | — | — | WO | claimed |
| WO-2024026307-A1 | BIOMARKER FOR LONG COVID AND FATIGUE | AXCELLA HEALTH INC. (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12606828-B2 | Aptamers for use in the treatment of Coronaviridae infections | APTA Therapeutics GmbH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NORTH CAROLINA STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4678749-A1 | NEUTRALIZABLE BLOOD COAGULATION INHIBITOR | The University of Tokyo (JP) | 2026-01-14 | — | — | EP | disclosed |
| WO-2025235814-A1 | POTENT ASGPR-BINDING HETEROBIFUCTIONAL COMPOUNDS FOR THE DEGRADATION OF TARGETED EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022214670-A1 | APTAMERS FOR USE IN THE TREATMENT OF CORONAVIRIDAE INFECTIONS | Berlin Cures GmbH (DE) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022058755-A1 | SELF-TARGETING EXPRESSION VECTOR | Lightbio Limited (GB) | 2022-03-24 | — | — | WO | disclosed |
| US-11282276-B2 | Collaborative light show authoring for tessellated geometries | CONTRAVENTUM, LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220056068-A1 | LIGAND DETECTION BY APTAMERS WITH A BUILT-IN REPORTER | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553054-B2 | Compositions and methods related to nucleic acid anticoagulants | NSUN2, NSUN3, ADAR | F2 16/4885TERT 340/4885POLB 635/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | F2 2402/4885TERT 4863/4885POLB 4359/4885 |
| US-12606828-B2 | Aptamers for use in the treatment of Coronaviridae infections | DNTT, TPT1, TEKT1 | F2 20/4885TERT 17/4885POLB 258/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885POLB 1103/4885 |
| US-20220056068-A1 | LIGAND DETECTION BY APTAMERS WITH A BUILT-IN REPORTER | IGF2R, NCS1, KCNJ6 | F2 4578/4885TERT 2383/4885POLB 3537/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | F2 4029/4885TERT 4830/4885POLB 4477/4885 |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | SERPINB1, ELANE, MPO | F2 794/4885TERT 429/4885POLB 628/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885POLB 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.